Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMM1NGC)

Drug Name
CERC 006 Drug Info
Synonyms
OSI-027; 936890-98-1; OSI027; OSI 027; 25MKH1SZ0M; AEVI-006; CERC-006; ASP-7486; 936890-98-1 (free acid); 4-[(5Z)-4-amino-5-(7-methoxyindol-2-ylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; (1r,4r)-4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; 1187559-66-5; trans-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; TRANS-4-[4-AMINO-5-(7-METHOXY-1H-INDOL-2-YL)IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL]CYCLOHEXANECARBOXYLIC ACID; UNII-25MKH1SZ0M; Cyclohexanecarboxylic acid, 4-[4-amino-5-(7-methoxy-1h-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-, trans-; CERC006; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo-[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; MLS006011006; SCHEMBL976795; SCHEMBL976796; CERC 006; CHEMBL2132692; CHEMBL3120215; SCHEMBL20482333; SCHEMBL22594988; SCHEMBL22787096; CHEBI:91363; ASP4786; ASP7486; EX-A143; JROFGZPOBKIAEW-HAQNSBGRSA-N; BDBM185151; DTXSID901025951; HMS3656H05; HMS3748I11; ASP 7486; BCP02613; NSC800810; s2624; AKOS030238938; AKOS037643584; AM81260; BCP9001034; CCG-268721; CS-0257; DB12387; NSC-800810; SB19259; NCGC00250395-01; NCGC00386179-01; NCGC00386179-04; NCGC00387858-03; (+/-)-Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; AC-31517; AS-17003; HY-10423; LS-14875; SMR004702804; SW220246-1; A-1065; F17371; J-523839; BRD-K94294671-003-01-3; Q27163231; Q27253978; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexane-1-carboxylic acid; 4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f] [1,2,4]Triazin-7-yl)cyclohexanecarboxylic Acid; 4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-2-indolylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]-1-cyclohexanecarboxylic acid; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)-imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid
Indication
Disease Entry ICD 11 Status REF
Lymphatic malformation LA90.1 Phase 1 [1]
Cross-matching ID
PubChem CID
135398516
TTD Drug ID
DMM1NGC

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Serine/threonine-protein kinase mTOR (mTOR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sirolimus DMGW1ID Advanced cancer 2A00-2F9Z Approved [3]
Temsirolimus DMS104F Renal cell carcinoma 2C90 Approved [4]
PF-04449913 DMSB068 Chronic myelomonocytic leukaemia 2A40 Approved [5]
Everolimus DM8X2EH Advanced cancer 2A00-2F9Z Approved [6]
Novolimus DM6ZPLQ Artery stenosis BD52 Approved [7]
Zotarolimus DMRMCXW Solid tumour/cancer 2A00-2F9Z Approved [8]
Ridaforolimus DMLHEU7 Sarcoma 2A60-2C35 Phase 3 [9]
AZD2014 DMOEARH Solid tumour/cancer 2A00-2F9Z Phase 2 [10]
MM-141 DM2RJ4D Pancreatic cancer 2C10 Phase 2 [11]
PQR309 DMMCYZ8 Squamous head and neck cell carcinom 2D60.0 Phase 2 [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Serine/threonine-protein kinase mTOR (mTOR) TTCJG29 MTOR_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT04994002) A Phase 1b, Open-Label, Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults (Aged 18-31 Years) With Complex Lymphatic Malformations. U.S.National Institutes of Health.
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
3 Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
4 Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014 Nov;35(11):604-20.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma. Gan To Kagaku Ryoho. 2009 Jul;36(7):1076-9.
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
8 Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep. 2008 Jun;25(3):475-516.
9 A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
10 Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014. Biochem Biophys Res Commun. 2014 Jan 10;443(2):406-12.
11 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)